Reference (Feb-22-E1)
Arjun Puranik, P.J.L., Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, View ORCID ProfileJohn C. O’Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, Venky Soundararajan (2021). Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv.
Bhattacharya, S., Banerjee, A., and Ray, S. (2021). Development of new vaccine target against SARS-CoV2 using envelope (E) protein: An evolutionary, molecular modeling and docking based study. Int J Biol Macromol 172, 74-81.
Lopandic, Z., Protic-Rosic, I., Todorovic, A., Glamoclija, S., Gnjatovic, M., Cujic, D., and Gavrovic-Jankulovic, M. (2021). IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. Int J Mol Sci 22.
Saumyabrata Mazumder, R.R., Avinash Undale, Kajal Arora, Nupur Mehrotra Arora, Biswa Pratim, Dilip Kumar, Abyson Joseph, Bhupesh Mali, Vidya Bhushan Arya, Sriganesh Kalyanaraman, Abhishek Mukherjee, Aditi Gupta, Swaroop Potdar, Sourav Singha Roy, Deepak Parashar, Jeny Paliwal, Sudhir Kumar Singh, Aelia Naqvi, Apoorva Srivastava, Manglesh Kumar Singh, Devanand Kumar, Sarthi Bansal, Satabdi Rautray, Indrajeet Singh, Pankaj Fengade, Bibekanand Kumar, Manish Saini, Kshipra Jain, Reeshu Gupta, View ORCID ProfilePrabuddha Kumar Kundu (2020). PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2. BioRxiv.
Troyano-Hernaez, P., Reinosa, R., and Holguin, A. (2021). Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week. Viruses 13.
